Pharmafile Logo
Pharmafocus logo
Advanced Search

UK

Showing 15 posts of 472 posts found.

drug_safety

Drug safety: UK and EU post-Brexit

September 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Europe, MHRA, UK, brexit, drug safety, pharmacovigilance

What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from …

Feature

NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis

September 10, 2018
Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

News

Pfizer says Brexit will cost the company $100 million

September 4, 2018
Manufacturing and Production EU, Pfizer, UK, brexit, pharma

The US multinational Pfizer has said that Brexit will cost the company $100 million in costs associated with the transference …

News
pharmafocus_oct_2018

The September 2018 issue of Pharmafocus is available to read online now!

September 3, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, AstraZeneca, Cancer, Iraw, J&J, JJ, Pfizer, Roche, UK, brexit, drug safety, pharma, pharmacovigilance

The new September edition of Pharmafocus is now live and available to read online. We’re entering the final stretch as …

News
28246711066_52e38bc591_z

MHRA loses EMA contracts in wake of Brexit

September 3, 2018
Sales and Marketing EMA, MHRA, UK, brexit, contracts, politics, regulation

The EMA has awarded Britain’s regulatory body the MHRA just two contracts this year, as the European agency suggested that …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 31, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten

Eight months of 2018 down – where has the year gone? As we move from August into September, and a …

News
credit_natural_cycles

Contraceptive app Natural Cycles investigated over “misleading” efficacy claims

August 30, 2018
Medical Communications, Sales and Marketing APP Pharma, Natural Cycles, UK, app. pharma

The company behind Natural Cycles, the first-ever approved smartphone app promising a natural alternative to contraception, has seen a Facebook …

News
european_commission_web

Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies

August 28, 2018
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

News
28246711066_52e38bc591_z

Government publishes no-deal Brexit guidance, health secretary tells pharma companies to stockpile medicines

August 24, 2018
Medical Communications ABPI, EU, UK, brexit, government, stockpiling

The British Government has published a document offering guidance as to what should be expected in the case of a …

News
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

August 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10

There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set …

News
4768764591_9e4f7f0eb8_z

ABPI Chief warns of Brexit impact on EU

August 10, 2018
Medical Communications ABPI, EU, UK, brexit, trade lobby

The head of the Association of the British Pharmaceutical Industry (ABPI) has warned that European governments have failed to recognise …

News
28246711066_52e38bc591_z

MHRA sets out Brexit implementation period plan

August 7, 2018
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, MHRA, UK, brexit, implentation period

The UK Medicines and Healthcare products Regulatory Agency (MHRA) have released an update which sets out what pharmaceutical and healthcare …

News
ema_logo

EMA to cut activities as it forecasts loss of 30% of staff

August 2, 2018
Medical Communications, Research and Development EMA, London, UK, amsterdam, brexit, disruption, staff

The European Medicines Agency is set to enact temporary cuts in activities as it prepares for significant disruption in the …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026